BioSustane for amorphous solid dispersion

Highly hydrophobic Eastman BioSustane™ SAIB NF can be used as a carrier for amorphous solid dispersions. This novel excipient does not need hot-melt extrusion or spray-drying manufacturing techniques. Traditional wet granulation techniques can be used to formulate BioSustane amorphous solid dispersions into tablets or capsules. When used as a carrier, BioSustane is shown to improve bioavailability by preventing recrystallization of poorly water-soluble APIs.

The solubility of some poorly water-soluble API in water versus BioSustane.
The solubility of the APIs in BioSustane improves multifold.
    BCS Class II and IV
Water solubility
BioSustane solubility
    Rifaximin7.1 36.36 ± 0.93 x 103
    Aripiprazole 7.7511.6 ± 29.6 x 103
    Dolutegravir 3.1761.7 ± 0.4 x 103
    Cyclosporine 4.0239 ± 12.6 x 103
    Tacrolimus 4.02 143.1 ± 28.3 x 103
    Sirolimus 1.73 1.92 ± 0.04 x 103
    Aprepitant 3-7 0.39 ± 0.04 x 103
    Carbamazepine 152 76.54 ± 4.04 x 103

BioSustane prevents recrystallization of the poorly water-soluble API. When used as carrier for an amorphous solid dispersion, BioSustane forms a stable dispersion. A study of several weeks of aprepitant formulation with BioSustane through X-ray diffraction revealed no peaks, indicating BioSustane forms a stable, amorphous solid dispersion that inhibits API recrystallization.

BioSustane prevents recrystallization of poorly water-soluble API

BioSustane prevents recrystallization

BioSustane is shown to improve bioavailability when used in formulation with other typical excipients. A formulation containing BioSustane and aprepitant, along with a few other excipients, showed two times more bioavailability compared to the formulation without BioSustane. Data of the bioavailability in beagles demonstrates BioSustane can be an effective and novel carrier for drug delivery of poorly water-soluble APIs.

BioSustane improves bioavailability of Aprepitant in beagles

BioSustane improves bioavailability

 Pharmacokinetics parameter Cmax (ng/mL) Tmax(h) AUC0–t (ng·h/mL) AUC0–∞ (ng·h/mL) T1/2 (h) Kel (1/h)
 BioSustane2522.9 ± 390.6325688.4 ± 2692.926589.6 ± 2624.413.2 ± 1.60.053 ± 0.007
 Physical mixture1214.2 ± 189.639784.9 ± 722.110499.4 ± 437.914.1 ± 3.30.05 ± 0.01